Table 1.
Baseline Demographics of All Participants
| Variable | Overall (n=101) | Composite outcomes (+) (n=16) | Composite outcomes (−) (n=85) | P value |
|---|---|---|---|---|
| Age, y | 75.2±5.3 | 76.8±6.3 | 75.0±5.0 | 0.22 |
| Male sex | 87 (86) | 13 (81) | 74 (87) | 0.55 |
| Body mass index, kg/m2 | 23.3±3.2 | 21.8±2.0 | 23.6±3.3 | 0.04 |
| NYHA≧III | 30 (30) | 9 (56) | 21 (25) | 0.01 |
| Prior heart failure hospitalization | 30 (30) | 9 (56) | 21 (25) | 0.01 |
| Hypertension | 50 (50) | 6 (38) | 44 (52) | 0.30 |
| Diabetes | 26 (26) | 7 (44) | 19 (22) | 0.07 |
| Atrial fibrillation | 56 (55) | 10 (63) | 46 (54) | 0.54 |
| hs‐cTnT, ng/mL | 0.049 (0.036–0.072) | 0.083 (0.056–0.100) | 0.044 (0.035–0.060) | <0.01 |
| BNP, pg/mL | 167 (102–267) | 248 (146–521) | 166 (93–249) | 0.02 |
| eGFR, mL/min per 1.73 m2) | 52.7±13.8 | 46.9±15.3 | 53.8±13.3 | 0.06 |
| Biomarker staging* | ||||
| Score 0–1 (low risk) | 68 (67) | 3 (19) | 65 (76) | <0.01 |
| Score 2–3 (high risk) | 33 (33) | 13 (81) | 20 (24) | |
| IVSd, mm | 15.6±2.3 | 15.1±1.9 | 15.6±2.4 | 0.44 |
| LVEF, % | 50.2±10.3 | 46.5±10.3 | 50.9±10.2 | 0.12 |
| QRS duration, ms | 112±27 | 117±29 | 111±27 | 0.46 |
| H/CL ratio† | 1.93±0.35 | 1.98±0.25 | 1.92±0.36 | 0.61 |
| Native T1, ms‡ | 1427±54 | 1456±52 | 1423±54 | 0.08 |
| ECV, %§ | 57.1±13.8 | 69.3±10.2 | 55.2±13.3 | <0.01 |
| ACEI/ARB | 47 (47) | 6 (38) | 41 (48) | 0.43 |
| ARNI | 4 (4) | 0 (0) | 4 (5) | 0.24 |
| β‐Blocker | 24 (24) | 6 (38) | 18 (21) | 0.16 |
| Diuretics | 70 (69) | 13 (81) | 57 (67) | 0.24 |
| Dose of loop diuretics|| | 19.5±15.8 | 25.3±17.3 | 18.3±15.3 | 0.12 |
| MRA | 41 (41) | 10 (63) | 31 (36) | 0.052 |
| SGLT2 inhibitor | 13 (13) | 4 (25) | 9 (11) | 0.14 |
Data are given as mean±SD, number (percentage), or median (interquartile range). ACEI/ARB indicates angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BNP, B‐type natriuretic peptide; ECV, extracellular volume; eGFR, estimated glomerular filtration rate; H/CL, heart/contralateral; hs‐cTnT, high‐sensitivity cardiac troponin T; IVSd, interventricular septal thickness in diastole; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; and SGLT2, sodium‐glucose cotransporter 2.
Score calculated by adding 1 point if hs‐cTnT (cutoff value >0.05 ng/mL) and BNP (cutoff value >250 pg/mL) levels increased and eGFR level (cutoff value <45 mL/min/1.73 m2) decreased more than the cutoff value.
Data available in 83 patients.
Data available in 74 patients.
Data available in 67 patients.
Loop diuretic dose equivalent to furosemide.